These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30554792)

  • 1. Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland.
    Wranik WD; Zielińska DA; Gambold L; Sevgur S
    Health Policy; 2019 Feb; 123(2):191-202. PubMed ID: 30554792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
    Wranik WD; Gambold L; Peacock S
    Health Policy; 2021 Mar; 125(3):307-319. PubMed ID: 33388158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
    Denburg AE; Giacomini M; Ungar WJ; Abelson J
    Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany.
    Kieslich K
    Health Econ Policy Law; 2020 Jul; 15(3):370-385. PubMed ID: 30975237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
    Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
    Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study.
    Nicod E; Maynou L; Visintin E; Cairns J
    Health Econ Policy Law; 2020 Jul; 15(3):386-402. PubMed ID: 31488229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When health technology assessment is confidential and experts have no power: the case of Hungary.
    Csanádi M; Löblová O; Ozierański P; Harsányi A; Kaló Z; McKee M; King L
    Health Econ Policy Law; 2019 Apr; 14(2):162-181. PubMed ID: 29576025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical and Social Values for Paediatric Health Technology Assessment and Drug Policy.
    Denburg AE; Giacomini M; Ungar W; Abelson J
    Int J Health Policy Manag; 2022 Mar; 11(3):374-382. PubMed ID: 32801223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The politics of health technology assessment in Poland.
    Ozieranski P; McKee M; King L
    Health Policy; 2012 Dec; 108(2-3):178-93. PubMed ID: 23127957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital-based technology assessment programmes: two Canadian examples.
    Juzwishin D; Olmstead D; Menon D
    World Hosp Health Serv; 1996; 32(2):2-9. PubMed ID: 10165872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.